financetom
Business
financetom
/
Business
/
WW Grainger raises profit forecast as maintenance demand remains strong
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
WW Grainger raises profit forecast as maintenance demand remains strong
Aug 4, 2026 6:33 AM

Aug 4 (Reuters) - WW Grainger ( GWW ) raised its 2026

earnings forecast on Tuesday after reporting

better-than-expected quarterly profit, as steady demand for

maintenance and repair services boosted the industrial tools

supplier's performance.

Geopolitical uncertainty and tariff concerns have prompted

companies to delay capital expenditures, choosing instead to

repair and maintain existing equipment for longer use, which is

lifting demand for suppliers such as WW Grainger ( GWW ).

However, shares of WW Grainger ( GWW ) were down 5.4% in premarket

trading.

Here are some details:

* The toolmaker expects 2026 adjusted profit between $45.50

and $47.25 per share, compared with its previous forecast range

of $44.25 to $46.25 per share.

* Sales remained strong despite ongoing geopolitical

uncertainty, and core operating profitability was in line with

expectations, the company said.

* The company posted a quarterly profit of $12.01 per share,

up from $9.97 per share a year earlier and above analysts'

average estimate of $11.31 per share.

* The high-touch solutions unit, WW Grainger's ( GWW ) largest

segment that serves large to mid-size companies with

maintenance, repair and operations services, posted an 11.9%

rise in sales in the second quarter from a year ago.

* Total revenue for the quarter ended June 30 was $5

billion, up from $4.55 billion a year earlier. Analysts, on

average, had expected $4.95 billion.

* On Monday, the company said Chief Financial Officer Deidra

Merriwether would step down effective September 4, and Laurie

Thomson would take on the role on an interim basis.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Amgen to Submit Thyroid Eye Disease Treatment Marketing Authorization Application in Europe
Amgen to Submit Thyroid Eye Disease Treatment Marketing Authorization Application in Europe
Apr 26, 2024
11:00 AM EDT, 04/26/2024 (MT Newswires) -- Amgen ( AMGN ) said Friday it will submit a marketing authorization application to the European Medicines Agency for the teprotumumab medicine to treat moderate to severe thyroid eye disease in adults. Teprotumumab is approved for thyroid eye disease treatment in the US, Brazil and Saudi Arabia under the brand name Tepezza, the...
Update: AppFolio Swings to Q1 Adjusted Earnings, Revenue Rises; Lifts 2024 Revenue Guidance; Shares Climb
Update: AppFolio Swings to Q1 Adjusted Earnings, Revenue Rises; Lifts 2024 Revenue Guidance; Shares Climb
Apr 26, 2024
11:01 AM EDT, 04/26/2024 (MT Newswires) -- (Updates with stock price movement in the headline and first paragraph) AppFolio ( APPF ) shares were up more than 16% in recent trading on Friday, a day after the company posted stronger-than-expected Q1 earnings and raised 2024 revenue guidance. The company reported late Thursday it swung to Q1 adjusted earnings of $1.05...
Biodexa Pharmaceuticals Gets Exclusive License for Phase 3 Ready Drug to Treat Familial Adenomatous Polyposis -- Shares Jump
Biodexa Pharmaceuticals Gets Exclusive License for Phase 3 Ready Drug to Treat Familial Adenomatous Polyposis -- Shares Jump
Apr 26, 2024
10:56 AM EDT, 04/26/2024 (MT Newswires) -- Biodexa Pharmaceuticals ( BDRX ) said Friday it has signed a deal with Emtora Biosciences for the exclusive, global rights for eRapa, a phase 3-ready drug to treat familial adenomatous polyposis, an inherited condition that affects the gastrointestinal tract. Shares of the company rose more than 81% in recent Friday trading. The license...
Update: ResMed's Fiscal Q3 Non-GAAP Earnings, Revenue Increase; Shares Up Over 17%
Update: ResMed's Fiscal Q3 Non-GAAP Earnings, Revenue Increase; Shares Up Over 17%
Apr 26, 2024
11:01 AM EDT, 04/26/2024 (MT Newswires) -- (Updates to include recent stock movement in the headline and first paragraph.) ResMed ( RMD ) shares rose by more than 17% in recent Friday trading after the company reported fiscal Q3 non-GAAP earnings of $2.13 per diluted share, up from $1.68 a year earlier. Analysts surveyed by Capital IQ expected $1.91. Revenue...
Copyright 2023-2026 - www.financetom.com All Rights Reserved